Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.View ...

The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

On October 22, 2024, Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide products ...

Novo Nordisk (NYSE:NVO) is one of the most profitable value stocks to buy according to analysts. On July 25, Novo Nordisk announced that the European Medicines Agency’s Committee for Medicinal ...

Ltd. (Novo Nordisk) today announced the successful completion of the Affordability Project in Thailand as part of its ongoing ...

Novo Nordisk’s shares plunged more than a fifth on Tuesday, wiping more than €60bn from its value, after it slashed sales and profit forecasts for the year amid competition from US copycat weight-loss ...

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...